PATHOLOGICAL UTERINE BLEEDING DURING REPRODUCTIVE AGE AND PREMENOPAUSE (ASPECTS OF DIAGNOSIS AND TREATMENT)
Keywords:Pathologycal bleeding, uterus, treatment, dufaston
Pathological uterine bleeding is one of the significant problems in gynecology. Different aspects of abnormal bleeding are discussed (classification, causal factors, mechanisms, diagnosis, treatment). Medications are assessed according their priorities (haemostatic effect; regulation of menstrual cycle). Preferences of dufaston are underlined: a) It doesn’t characterize by undrogenic, glucocorticoidal and mineralocorticoidal action; b) It doesn’t aggravate insuline resistance and dyslipidemic disorders, or affect the haemostatic system.
Behera M.A., Lucidi R.S. What is role of progestins in the treatment of abnormal uterine bleeding (AUB)? Medscape. July 16, 2020.
Bradley L.D. Gueye N.A. The medical management of abnormal uterine bleeding in reproductive-aged women. Am. J. Obstet. Gynecol. 2016; 214(1): 31-44.
Cheng Y. J., Liu Z.H., et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis PLOS Med. 2013; 10(9): c1001515.
Colombo N., Preti E., et al. ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(Suppl.6): vi 33-8.
Combined hormonal contraception and the risk of venous thromboembolism: a guideline/Practice Committee of American Society for reproductive medicine. Fertil. Steril. 2017; 107(1): 43-51.
Critchley H.O., Maybin J.A., et al. Physiology of the endometrium and regulation of menstruation. Physiol. Rev. 2019; 100(3): 1149-79.
Garry R., Hart R., et al. A re-appraisal of the morphological changes within the endometrium during menstruation: a hysteroscopic, histological and scanning electron microscopic study. Hum. Reprod. 2009; 24(6): 1393-401.
Griesinger G., Toumaye H., et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod. Biomed. Online. 2019; 38(2): 249-59.
Hapangama D.K., Kamal A.M., et al. Estrogen receptor beta: the guardian of the endometrium. Hum. Reprod. Update. 2015; 21(2): 174-93.
Hapangama D.K., Bulmer J.N. Pathophysiology of heavy menstrual bleeding. Women’s Health. 2016;12/1:3-13
Heavy menstrual bleeding: assessment and management. NICE guideline. NICE: National Institute for Health and Clinical Excellence; 14 March 2018.
Jabbour H.N., Kelly R.W. et al. Endocrine regulation of menstruation. Endocr. Rev. 2006; 27(1):17-46.
Kapustin R.V., Arzhanova O.N., et al. Exogenous progesterone as a factor for the development of gestational diabetes melitus. Rossiyskiy vestnik akushera-ginekologa. 2019; 19(1): 38-45. (In Russian).
Kareva E.N. Thrombosis and gestagens. Doctor. Ru. 2019; (7): 57-64. (In Russian).
Karlson T.S., Marions L.B. et al. Heavy menstrual bleeding significantly affects quality of life. Acta Obstet. Gynecol. Scand. 2014; 93(1): 52-7.
Kumar P., Sharma A. Gonadotropin – releasing hormone analogs: Understanding advantages and limitations. J. Hum. Reprod. Sci. 2014; 7(3):170.
Lethaby A., Duckitt K., et al. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst. Rev, 2013; (1): CD000400.
Lidegaard O., Milson I., et al. Hormonal contraception and Venous thromboembolism. Acta Obstet. Gynecol. Scand. 2012; 91(7): 769-78.
Madden T., Secura G.M., et al. The role of contraceptive attributes in women’s contraceptive decision making. Am. J. Obstet. Gynecol. 2015; 213(1): 46.
Maxwell D., Jacob M., et al. Selection of contraceptive therapy for patients with thrombophilia: a review of the evidence. J. Women’s Health. 2014; 23(4): 318-26.
Maybin J.A., Critchley H.O. Menstrual physiology: implications for endometrial pathology and beyond. Hum. Reprod. Update. 2015; 21(6): 748-61.
Munro M.G., Critchley H.O. et al. FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil. Steril. 2011; 95(7): 2204-08.
Munro M.G., Critchley H.O. et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions Int. J. Gynecol. Obstet. 2018; 143(3): 393-408.
Nouri M. Tavakkolian A. et al. Association of dysfunctional uterine bleeding with high body mass index and obesity as a main predisposing factor. Diabetes Metab. Syndr. Jan-Mar 2014; 8(1): 1-2.
Ordi J., Bergeron C., et al. Reproducibility of current classifications of endometrial endometrioid glandular proliferations: Further evidence supporting a simplified classification. Histopathology. 2013; 64(2): 284-92.
Park J.C., Lims S.Y., et al. Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome. Clin. Exp. Reprod. Med. 2011; 38(1): 42-6.
Pinkerton J.A.V. Pharmacological therapy for abnormal uterine bleeding. Menopause. 2011; 18(4): 453-61.
Plavinsky S.L., Barinova A.N., et al. Adverse outcomes of using hormonal drugs. An analysis of pharmacoepidemiological research works and spontaneous reporting databases. Voprosy ginekologii, akusherstva i perinatologii. 2019; 18(6): 92-9. (In Russian).
Podzalkova N.M., Glazkova O.L. Simptom, sindrom, diagnoz. Differential’naya diagnostika v ginekologii. 3rd Moscow; GEOTAR-Media; 2014. 736p. (In Russian).
Podzalkova N., Tatarchuk T., et al. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol. Endocrinol. 2016; 32(3): 246-9.
Podzalkova N.M., Tatarchuk T.F., et al. Menstrual cycle normalization with dydrogesterone. Akusherstvo i ginekologiya. 2018; (6): 70-5. (In Russian).
Royal College of Obstetricians and Gynaecologists. National menstrual heavy bleeding audit. Second Annual Report. London, UK: Royal College of Obstetricians and Gynaecologists; 2012.
Sibirskaya E.V., Pivazyan L.G. Hormonal therapy for management of abnormal uterine bleeding in women of late reproductive age. Vopr. Ginekol. Akus. Perinatol. 2020; 19(2): 129-35. (In Russian).
The American College of Obstetricians and Gynecologists. Abnormal uterine bleeding. FAQ: Gynecologic Problems.
Trivedt N., Chauhan N., et al. Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study. Gynecol. Endocrinol. 2016; Mar. 7:1-5.